Daniella Veloria

Safety of Additional Local Anesthetics Soon After Liposomal Bupivacaine: A Retrospective Cohort Study

Daniella Veloria, Lei Xu, Elizabeth Rader, David Ha et autres

Introduction Liposomal bupivacaine (LB) produces a prolonged serum bupivacaine level. It carries a warning to avoid additional local anesthetics for 96 hours due to a theoretical additive risk of local anesthetic systemic toxicity (LAST). Whether patients exposed to additional local anesthetics soon …

us (code pays fourni par la source)

Droxidopa for Intravenous Vasopressor Weaning in the Intensive Care Unit: A Descriptive Study

Calvin Diep, Daniella Veloria, Amy Kloosterboer

Background/Objectives: Our objective was to describe the safety and efficacy of enteral droxidopa, a norepinephrine prodrug, for intravenous (IV) vasopressor weaning in intensive care unit (ICU) patients. Methods: This was a single-center, retrospective descriptive study of adult ICU patients. Patients who received …

us (code pays fourni par la source)

Reduced versus full apixaban lead-in dosing following parenteral treatment of acute venous thromboembolism

Daniella Veloria, Benjamin X. Wang, Ran Ran, David Ha et autres

914: USE OF DROXIDOPA TO FACILITATE INTRAVENOUS VASOPRESSOR WEANING IN CRITICALLY ILL PATIENTS

Calvin Diep, Daniella Veloria, Karissa Koessel, Amy Kloosterboer

us (code pays fourni par la source)

Beyond the basics: rethinking antimicrobial stewardship by targeting cytomegalovirus immune globulin for immunocompromised patients

Ritika Prasad, Brian Lu, Daniella Veloria, Emily Mui et autres

Identifying actionable stewardship targets in immunocompromised patients is challenging due to limited data and high morbidity. One approach could be targeting therapy with limited evidence, like cytomegalovirus immune globulin (CMV-IGIV). We implemented a drug restriction program that increased appropriate use of CMV-IGIV, …

us (code pays fourni par la source)